Respicardia Inc. received FDA approval for its Remedē system for central sleep apnea (CSA), widening treatment options for the condition often tied to negative cardiovascular impact. The implantable device stimulates the phrenic nerve automatically to impact the diaphragm while a patient sleeps. Read More
